These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of enzaprost F on the dilatation of cervical canal following intracervical and extra-ovular application in the first trimester of pregnancy.
    Author: Pajor A, Matányi S, Lintner F, Soltész K, Siklós P, Hintalan A.
    Journal: Ther Hung; 1985; 33(4):193-7. PubMed ID: 3870230.
    Abstract:
    Primigravidas ranging in age from 14-24 years who presented themselves for lawful abortion in the 7th-12th week of pregnancy were distributed into 2 groups to examine whether Enzaprost F (Chinoin) may be used in form of intracervical tablet and extraovular solution for preoperative cervix dilatation in the 1st trimester of pregnancy. In 1 group (n = 210), 10 cervical tablets were introduced into the cervical canal under aseptic circumstances following vaginal exposure by using the ascending tube of Szontagh's IUD. The tablets contained in 200 cases 2.5 mg prostaglandin F2alpha (Pgf2alpha) each (Enzaprost F cervical tablet, Chinoin) and in 10 cases only carrier substance (placebo). The dilatation of cervical canal was measured by means of Hegar's dilators prior to the introduction of the PGF2alpha containing tablets in 80 cases, 2 hours subsequently in 111 cases, and 3-4 hours subsequently in 89 cases, directly before emptying the uterus. If the dilatation of cervical canal failed to reach 11 mm after the preoperative treatment this was dilated further with Hegar's dilators directly before emptying the uterus. In the placebo group the dilatation of cervical canal was measured by the same method before and 2 and 4 hours after the application of tablets. In the other group (n = 45), pregnant women were ranged who had 2nd grade purity of vagina due to previous local vaginal treatment. In the 7th-12th week of pregnancy, the effect of 10 Enzaprost F cervical tablets was observed to be a function of time. The average dilatation of cervical orifice was 5.0 mm before treatments. 2 hours after the application of PGF2alpha, the cervical canal was dilated to 6.9 and 3-4 hours later to 8.5 mm. In response to 1.0 Enzparost F solution containing 1.0 mg active substance injected into the uterus through Foley catheter the cervical canal dilated within 3 hours to in average 8.1 mm, within 18 hours to in average 10.9 mm. The dilatation of the cervical canal measured after 18 hours did not differ significantly from the value obtained after 3 hours. The dilatation of cervical canal measured before treatment in the group of placebo-treated primigravidas was in average 4.6 mm and in hours 2 and 4 of treatment 4.8 and 4.9 mm, respectively. The difference was statistically nonsignificant. Temporary mild systemic unwanted effect occurred in 35% of patients treated with Enzaprost F cervical tablets and in 88% of women subjected to extraovular treatment.
    [Abstract] [Full Text] [Related] [New Search]